ScreenerHero

HROW Harrow, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · harrow.com
30.35USD-0.75%Mkt Cap: 1.14B $P/E: —

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segment…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.69BUSDP/E 25.5
TAK
Takeda Pharmaceutical Company Limited
$57.82BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.64BUSDP/E 65.2
HLN
Haleon plc
$39.01BUSDP/E 18.1
ZTS
Zoetis Inc.
$29.48BUSDP/E 11.7
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
UTHR
United Therapeutics Corporation
$23.23BUSDP/E 19.4
VTRS
Viatris Inc.
$20.15BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.27BUSDP/E 111.6
NBIX
Neurocrine Biosciences, Inc.
$14.79BUSDP/E 21.3
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.23BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.40BUSDP/E 28.4
KRK
Krka, d. d.
$8.63BUSDP/E 19.3
AMRX
Amneal Pharmaceuticals, Inc.
$7.07BUSDP/E 41.4
ALKS
Alkermes plc
$6.99BUSDP/E 109.6
HIMS
Hims & Hers Health, Inc.
$6.88BUSD
LNTH
Lantheus Holdings, Inc.
$6.53BUSDP/E 24.2
KNSA
Kiniksa Pharmaceuticals International, plc
$5.93BUSDP/E 77.9
APTX
Apotex Health Corp.
$5.27BUSD

Key Statistics

Company
Market Cap1.14B USD
Enterprise Value1.36B USD
Revenue (TTM)275.59M USD
Gross Profit204.37M USD
Net Income (TTM)-5.14M USD
Revenue/Share7.40 USD
Last Price30.35 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees373
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)10.76
PEG—
EV/EBITDA76.64
EV/Revenue4.93
P/S4.15
P/B75.07
EPS (TTM)-0.99
EPS (Forward)2.83
52W Range
28.547% of range54.85
52W High54.85 USD
52W Low28.54 USD
Profitability
Gross Margin75.05%
Oper. Margin-15.58%
EBITDA Margin6.43%
Profit Margin-1.89%
ROE-9.80%
ROA-1.29%
Growth
Revenue Growth10.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF43.86M USD
CapEx (TTM)1.10M USD
FCF Margin-1.99%
FCF Yield-0.48%
Net Debt215.43M USD
Net Debt/EBITDA12.16
Balance Sheet
Debt/Equity4.80
Current Ratio2.24
Quick Ratio2.00
Book Value/Sh0.41 USD
Cash/Share2.28 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:5
Split DateFeb 8, 2013
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)65.00 USD
Upside (mean)+114.2%
Target Range45.00 USD – 88.00 USD
45.00+114.2% to mean88.00
# Analysts9
Ownership
Shares Out.37.49M
Float28.93M
Insiders15.38%
Institutions58.58%
Short Interest
Short Ratio15.2d
Short % Float22.23%
Short % Out.19.98%
Shares Short7.49M
Short (prev mo.)6.36M
Technical
SMA 5037.12 (-18.2%)
SMA 20040.35 (-24.8%)
Beta0.24
S&P 52W Chg14.58%
Avg Vol (30d)526.42K
Avg Vol (10d)508.41K
Technical Indicators
RSI (14)26.2
MACD-2.1139
MACD Signal-1.9442
MACD Hist.-0.1696
BB Upper38.64 USD
BB Middle33.52 USD
BB Lower28.39 USD
BB Width30.59%
ATR (14)1.392 USD
Vol Ratio (20d)0.73x